key: cord-0809237-ahq57bld authors: Oddy, Christopher; McCaul, James; Keeling, Polly; Allington, Jonathan; Senn, Dhanuja; Soni, Neesha; Morrison, Hannah; Mawella, Ruwani; Samuel, Thomas; Dixon, John title: Pharmacological Predictors of Morbidity and Mortality in COVID‐19 date: 2021-04-28 journal: J Clin Pharmacol DOI: 10.1002/jcph.1878 sha: f995bfe1608eda295a520fde3158af10bca2ff31 doc_id: 809237 cord_uid: ahq57bld The interaction of COVID‐19 with the majority of common prescriptions is broadly unknown. The purpose of this study is to identify medications associated with altered disease outcomes in COVID‐19. A retrospective cohort comprised of all adult inpatient admissions to our centre with COVID‐19 was analysed. Data concerning all antecedent prescriptions were collected and agents brought forward for analysis if prescribed to at least 20 patients in our cohort. Forty‐two medications and 22 classes of medication were examined. Groups were propensity score matched and analysed by logistic and linear regression. The majority of medications did not show a statistically significant relationship with altered disease outcomes. Lower mortality was associated with use of pregabalin (p = 0.049, HR = 0.10 [0.01‐0.92]), inhalers of any type (p = 0.015, HR = 0.33 [0.14‐0.80]) and specifically beclomethasone (p = 0.032, HR = 0.10 [0.01‐0.82]), tiotropium (p = 0.035, HR = 0.07 [0.01‐0.83]) and steroid containing inhalers (p = 0.013, HR = 0.35 [0.15‐0.79]). Gliclazide (p = 0.020, HR = 4.37 [1.26‐15.18]) and proton pump inhibitor (p = 0.028, HR = 1.72 [1.06‐2.79]) use was associated with greater mortality. Diuretic (p = 0.002, HR = 0.07 [0.01‐0.37]) and statin (p = 0.006, HR = 0.35 [0.17‐0.73]) use was associated with lower rates of critical care admission. Our data lends confidence to observing usual practice in COVID‐19 patients by continuing antecedent prescriptions in the absence of an alternative acute contraindication. We highlight potential benefits in investigation of diuretics, inhalers, pregabalin and statins as therapeutic agents for COVID‐19 and support further assessment of the safety of gliclazide and PPIs in the acute illness. This article is protected by copyright. All rights reserved Introduction SARS-CoV-2 has represented an unprecedented challenge for clinicians in 2020. Uncertainty in dayto-day decision making is familiar to clinicians working with patients admitted with COVID-19. The absence of clear, evidence-based, guidelines make clinical judgements surrounding these patients complex. Polypharmacy in the UK is common in hospitalised patients 1 . It is well understood that prescription medications can cause iatrogenic harm, and that acute illness may render medications, that are otherwise well tolerated, harmful to their recipients 2 . The interaction of COVID-19 with the multitude of agents prescribed to many individuals is broadly unknown. A limited number of studies have examined certain classes of medication in the context of SARS-CoV-2 infection, revealing several robust associations [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Some point to the clear opportunity for adjusting prescriptions to the benefit of patients admitted with COVID-19 with greater understanding of how the disease interacts with commonly used agents 6 . Evidently there is much still to be understood about how outcomes in COVID-19 are affected by individuals' prior prescriptions, and benefits to exploring this. Identifying medications associated with worsened outcomes in COVID-19 may be of additional benefit in risk stratification. The prescription of certain agents is reserved for only severe or uncontrolled disease, and their prescription therefore may inform clinicians about the severity of an individual's prior conditions. Current risk prediction models rely on demographic characteristics and comorbidities alone [20] [21] [22] . Identifying agents that are associated with morbidity and mortality in COVID-19 might therefore be valuable, alongside these matrices, in signposting highly comorbid patients that are vulnerable to severe disease. This may be especially pertinent when the severity of a patient's prior conditions is unknown. The purpose of the present study is to identify medications associated with altered disease outcomes in COVID-19 by examining all antecedent prescriptions held by participants in our cohort. The study received sponsorship from Epsom and St Helier University Hospitals NHS Trust. The requirement for ethical review was waived by The Office for Research Ethics Committees Northern Ireland (IRAS ID: 283834). A retrospective cohort comprised of all adults admitted to our centre with confirmed SARS-CoV-2 infection between the 10 th of January 2020 and the 1 st of June 2020 was analysed. Infection was confirmed in all cases by detection of SARS-CoV-2 RNA on nasal/oropharyngeal swab. Patients were included if their admissions data listed COVID-19 as the primary or secondary reason for admission, or if COVID-19 was documented as the primary (1a) or secondary (1b) cause of death on their medical certificate of cause of death (MCCD). Patients meeting these criteria were excluded if their admission was ongoing or uncoded by the 1 st of August 2020. Admissions with a primary or secondary diagnosis of COVID-19 were selected to prevent morbidity associated with unrelated clinical sequelae being reflected in analyses. The order of diagnosis codes is assigned according to their clinical significance, related morbidity, and implications for management. Numerous patients were excluded by this criterion and most likely represent mild or incidental cases. Patients meeting our inclusion criteria were collated by our search engine alongside admission data and coding comprising their demographic characteristics and past medical history. Antecedent prescriptions and outcomes data were extracted manually from electronic hospital records. Prescriptions were recorded according to their recommended international non-proprietary names (riNN). Mixed formulations were recorded as each of the components' riNN separated by a forward slash. Once collected, patients' prescriptions were systematically screened and categorised for analysis if 20 or more patients received a particular agent. Where possible during data extraction, guided by the wider literature, commonly prescribed classes of medication were identified and collated for analysis. Antecedent prescriptions Antecedent prescriptions were defined as active physician-ordered prescriptions prescribed to patients at the point of attendance at our centre for their COVID-19 related admission. Over the counter prescriptions were not considered. These were identified from emergency department notes for their COVID-19 related admission and general practice records. Additional medications were identified from inpatient pharmacist "medicine reconciliations" derived from individuals' NHS Summary Care Record (SCR). Our primary outcome measures were inpatient mortality and intensive care unit (ICU) admission. Secondary outcomes considered were maximum oxygen requirement (L/min), maximum National Early Warning Score 2 (NEWS-2), maximum C-reactive protein concentration (CRP, mg/L), and maximum acute kidney injury (AKI) stage. AKI was defined according to KDIGO creatinine criteria 23 . NEWS-2 score was calculated according to standards set by the Royal College of Physicians (UK) 24 . Maximum oxygen requirement for each patient was defined as the highest flow rate of oxygen delivered to a patient in litres per minute (L/min) for more than two sets of observations. This was in order to account for titration to saturations. Venturi device percentages were converted to L/min by the following conversion: 24% = 3L/min, 28% = 5L/min, 35% = 9L/min, 40% = 11L/min, 60% = 13.5L/min 25 . Patients requiring invasive or non-invasive positive pressure ventilation were given a maximal score of 15L/min allowing for comparison with the remainder of the cohort. Continuous variables were reported as mean values ± standard deviation (±SD). Categorical variables were reported as counts and percentages. Each group of participants that were prescribed a particular agent or class of medication underwent propensity score matching to balance baseline characteristics. Propensity scores were calculated using logistic regression, adjusting for factors relevant to the prescription of each agent, which are presented in Table 1 . Members of each group were matched with two control subjects using a "greedy nearest-neighbour" algorithm with replacement and a calliper of 0.0 to achieve optimal balance 26,27 . Cases without an appropriate match were discarded from analysis cohorts. Matching adequacy for each selected covariate was assessed by calculating standardised mean differences for each factor. A summary of unbalanced covariates for each matched sample in both cases and controls is presented in Table 1 . We performed propensity score matching 100 times for each group, as a bootstrapping process, sampling from the un-treated remainder of the cohort 28 . Participants selected from the un-treated remainder varied with each matching analysis provided they fulfilled all of the criteria specified in the algorithm. This was due to relatively small subgroup sizes and thus a large pool of potential untreated matches. Hence, post-matching analysis was conducted on each matched cohort separately and an average of each of the 100 analyses calculated. Discarded treated cases and unbalanced factors in each matched cohort for a particular medication were the same due to strict specified criteria, samples of which were checked manually throughout. Post-matching analysis was conducted using logistic and linear regression models. Logistic models were employed where the dependent variable was binary -our primary outcome measureswhereas linear models were used when analysing continuous dependent variables. Results were reported as hazard ratios (HR) with 95% confidence intervals (CI), and p-values; each of which represent a bootstrapped average of the results from each of the 100 matched cohorts for each medication. Variables considered for post-matching adjustment were drawn from established risk prediction models and population analyses 20-22 . The "Enter" method was employed entering variables with a univariate logistic association with our primary outcome measure, mortality, with a p value of less than 0.2 into our models. Variables adjusted for were age, sex, ethnicity (white (any)/other), diabetes mellitus, chronic kidney disease (stage), hypertension, ischaemic heart disease, heart failure, heart rhythm disorders, valve disease, hyperlipidaemia, peripheral vascular disease, chronic obstructive pulmonary disease, asthma, other pulmonary disorders (bronchiectasis, pulmonary fibrosis), history of venous thromboembolism, history of cerebrovascular accident, dementia, osteoporosis, vitamin D deficiency, haematological cancer and organ transplant. No sample size calculation was performed because we were unable to find appropriate published data from which to calculate this prior to data collection. A two-sided α of less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22 (SPSS Inc., Chicago, Illinois). Six hundred and twelve admissions met our inclusion criteria, of which 354 (57.8%) were male. The average age of our cohort was 69.6 (±17.8) years. Four hundred and thirty-two (70.6%) of participants were of white ethnicity, the remaining 180 (29.4%) were Black-Asian minority ethnicities (BAME). Eighty-six patients (14.1%) were admitted to the ICU and 281 (45.9%) patients died. The rate of mortality in this cohort was escalated by our inclusion criteria excluding mild cases. Data was complete for each participant. Forty-two medications were prescribed to at least 20 study participants and were brought forward for analysis. A further 24 groups of medication were collated, and analysis was conducted on the resulting 66 categories. The distribution of prescriptions in our cohort, including agents that were not brought forward for analysis, is displayed in Figure S1 . The number of participants prescribed each medication, or class of medication, prior to admission is presented in Table 1 alongside: the mean age of each group; factors considered in each propensity matching algorithm; case and control numbers in each matched cohort; and a summary of unbalanced covariates after matching. Fiftynine of the 66 matched cohorts had no unbalanced covariates [ Table 1 ]. The relationships between each medication, or class of medication, and our primary outcome measures were explored, adjusting for age, sex, ethnicity and relevant comorbidities [ Table 2 ]. The majority of medications showed non-significant associations with mortality and critical care admission. Significantly lower mortality was associated with use of pregabalin (p=0.049, HR=0. Adjusted associations of each medication class with our secondary outcome measures: oxygen requirements [ Figure S4 ], NEWS-2 score [ Figure S5 ], CRP concentration [ Figure S6 ] and AKI stage [ Figure S7 ], are described [ Table 2 ]. Similarly to the primary outcomes, the majority of medications were not significantly associated with altered secondary outcomes. Our main findings are summarised in Figure 1 , with hazard ratios for all measured outcomes plotted together. The purpose of this study was to identify medications associated with altered disease outcomes in COVID-19, primarily with a view to assessing the safety of common agents. We demonstrate that the majority of medications were not significantly associated with altered disease outcomes. Whilst our subgroup sizes preclude drawing any strong conclusions regarding particular agents, it is clear that of the medications examined few are strongly associated with clinically significant morbidity. Given that our dataset affirms well established associations with similar subgroup sizes, for example the relationships of certain comorbidities with clinical outcomes, these findings can be contextualised. When examined through this lens we observe that the majority of medications examined did not alter risk of morbidity and mortality in COVID-19 as much as prior health conditions, for which we saw more marked effects. It is also worth noting that the majority of agents that had an association with outcomes conferred a diminished risk of adverse events. In practice our data implies that, in the absence of an alternative acute contraindication, there is no basis for suspending most antecedent prescriptions when patients are admitted to hospital with COVID-19. ACEi/ARBs in our cohort were significantly associated with higher rates of critical care admission and a greater rise in CRP, but not mortality. The proportionally large body of evidence on this topic favours ACEi/ARBs as generally protective against mortality and severe disease outcomes in COVID-19 8, 9 . Whilst our findings are incongruous with the wider literature, examination of this subgroup reveals that the majority of these patients did not receive their ACEi/ARBs in hospital -an intervention that we found to be strongly associated with poorer outcomes after adjustment for common reasons for ACEi/ARB suspension 29 . These observations may explicate the findings of the present study. Diuretics were associated with decreased rates of ICU admission, reduced oxygen requirements, and lower CRP. Hippisley-Cox observed a similar association of diuretics with reduced critical care admission in a cohort of 8.3 million participants, the relationship was however non-significant (p=0.102, HR=0.60 [0.32-1.11]) 17 . The relationship between diuretic use and mortality demonstrated here was non-significant, which has been observed previously 18 . The implication of these findings is that these agents may confer some protection against adverse outcomes in COVID-19, and are likely safe, but that the effect is modest in size. Gliclazide was shown to be significantly associated with increased mortality, greater oxygen requirements and rise in CRP, with all other outcome measures worsened. Gliclazide is an oral antihyperglycaemic (OAHG) that is prescribed as a second line adjunctive therapy in the management of type II diabetes if lifestyle changes and metformin alone do not achieve satisfactory control. It is plausible to speculate, then, that the effect observed here is due to participants in the sample having poorer diabetic control -rendering them susceptible to adverse outcomes. This effect, however, was not observed in patients prescribed any second line OAHG, bolstering the assertion that these effects are not simply related to worse premorbid condition. One study has examined the impact of sulphonylureas, a class of OAHGs of which gliclazide is a member, on critical care admission; concluding that their use is positively associated 17 . Further study of gliclazide, or more broadly sulphonylureas, in COVID-19 is clearly necessary to evaluate the safety of this agent in the acute setting. Use of inhalers of any formulation, and specifically steroid containing inhalers, was associated with lower mortality in our cohort. There are several plausible mechanisms by which inhalers might curtail harm caused by SARS-CoV-2 pneumonia. The available evidence surrounding inhaler use in COVID-19 is limited. One review compared outcomes in patients prescribed inhaled steroids with those taking other forms of inhaler, concluding that there was no indication that either conferred a greater risk of mortality than the other 19 . Presently there are no other studies comparing the outcomes of patients prescribed inhalers with appropriately matched controls, or interventional trials. A number of registered clinical trials are currently underway and represent the next stage in examining these as therapeutic agents. We show that PPI use is associated with greater mortality in a propensity matched analysis. Presently there are three peer reviewed publications that have examined the role of PPIs in COVID-19. Lee demonstrated that, in a nationwide propensity matched cohort including 14, 163 PPI users, PPI use was associated with a higher mortality (HR=1.63 [1.03-2.53]) 6 . Our analysis, using a considerably smaller sample size of 133, produced a similar effect size (HR=1.72 [1.06-2.79]). Ramachandran observed a similar phenomenon 7 . Almario showed that PPI use is associated with a higher likelihood of testing positive for SARS-CoV-2 infection 5 . The basis for these findings is presently purely speculative and is explored in detail in the aforementioned publications [5] [6] [7] . Importantly, PPIs represent a medication that could be safely suspended during acute COVID-19 illness given their indication is commonly for symptomatic relief. Suspension of PPIs might, therefore, be a suitable subject for future randomised control trials. Our findings corroborate previously observed associations of PPI use and worsened outcomes in COVID-19 and thus support further inquiry into this matter. Pregabalin was associated with reduced mortality, lower CRP and showed non-significant improvement in all other outcome measures. No patients who were prescribed pregabalin were admitted to ICU, although the small sample size renders this likely to be a chance phenomenon. The association of pregabalin with mortality may relate to downregulation of ACE2, the SARS-CoV-2 functional receptor, associated with its use 30 . Further retrospective data with larger sample sizes would be required to examine this association further prior to justifying unlicensed use as a therapy for COVID-19. The impact of statin use in COVID-19 patients has been an active matter of debate. Statins have been shown to be associated with reduced rates of ICU admission, diminished symptom severity and lower mortality [10] [11] [12] [13] . We observed a significantly reduced risk of critical care admission associated with statin use and a non-significant reduction in mortality, the latter of which may have been in relation to our subgroup size. Vitamin D deficiency has been consistently observed to be associated with poorer disease outcomes in COVID-19 3,4 . We did not observe any significant associations of vitamin D supplementation with outcomes in our cohort, although non-significant improvement in all of our outcome measures was shown. This may be due to a combination of a small sample size, a modest effect size of vitamin D supplementation and a lack of adjustment for serum vitamin D concentration. There are several inherent limitations to delineating causality from purely retrospective observational data that our study shares with all publications of this nature. Specifically, our study is limited by our sample size. Whilst subgroup sizes were adequate for several classes of medication the majority of subgroups for individual agents were fairly small, making our findings prone to both type I and type II error. We examined all antecedent prescriptions and set an arbitrary minimum of 20 participants receiving a particular medication, or class of medication, as an entrance criterion for analysis. No strong conclusions can be made about many of the agents we examined, although it is worth nothing that this was not the aim of our study. Our primary aim was to identify medications associated with morbidity and mortality in patients admitted to hospital with COVID-19. Whilst we collected data on all medications, a large number of agents and classes of agent were not brought forward for analysis and thus remain unexamined. Additionally, the absence of certain medical specialities at our centre will have prevented gathering data on medications common to the conditions managed under them. Whilst we extracted data from several sources to identify antecedent prescriptions, it is possible that these data were incomplete. Data was not collected on the duration of use of each prescription, nor on their inpatient use. Subgroup analysis of patients who had only recently received prescriptions or who had had their prescriptions suspended in hospital may have strengthened, or revealed, some associations. Finally, the use of propensity score matching to balance baseline characteristics is prone to bias. Unmeasured factors, such as premorbid disease severity, were not incorporated into the matching analysis and may have been unbalanced between groups. Additionally, whilst subjects might be matched appropriately, due to our small subgroup sizes it is possible that matched controls were not representative of the population at large. There are also numerous methods of propensity score matching, use of one over another having potential to alter results. We demonstrate that numerous common prescriptions do not associate with altered disease outcomes in patients hospitalised with COVID-19. Our data lends confidence to observing usual practice in patients admitted with SARS-CoV-2 infection by continuing antecedent prescriptions in the absence of an alternative acute contraindication. Our data corroborates several previously demonstrated associations and exhibit some novel interactions. We highlight potential benefits in investigation of diuretics, inhalers, pregabalin and statins as therapeutic agents for COVID-19 and support further assessment of the safety of gliclazide and PPIs in the acute illness. Our findings provide valuable pilot data for future studies to draw from, and from which power calculations can be performed. The associations demonstrated here offer a basis for further examination of particular agents in the context of COVID-19 in studies appropriately powered to examine an effect. Maldonado E, Tao D, Mackey K. Antithrombotic Therapies in COVID- Variables entered into propensity score matching algorithms for each medication are displayed in column four. Columns five and six display the numbers of cases and controls in each cohort after matching -both cases and controls were discarded during matching if an appropriate match could not be found. Columns seven and eight display unbalanced covariates after matching, with column seven displaying covariates that were higher or more frequent in the treated group, and column eight the un-treated group. Individual agents are listed first followed by classes of medication. Medications are displayed according to their recommended international non-proprietary names (riNN). Mixed formulations are recorded as each of the components' riNN separated by a forward slash. SD = standard deviation. The epidemiology of polypharmacy Adverse drug reactions: definitions, diagnosis, and management Role of vitamin D in preventing of COVID-19 infection, progression and severity Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19 Association of renin-angiotensinaldosterone system inhibitors with mortality and testing positive of COVID-19: Metaanalysis ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents Meta-analysis of Effect of Statins in Patients with COVID-19 Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Adjusted hazard ratios (HR ±95% CI) for primary and secondary outcomes imparted by each medication listed. Hazard ratios are expressed as the likelihood of a 5L/min increase for oxygen requirements, 5 point increase for NEWS-2 score and 100mg/L for CRP concentration. Significant associations are colourised with hazard ratios displayed in bold. The p value for each relationship is plotted adjacent. The selected agents are listed alphabetically. Pregabalin was taken exclusively by participants that did not require ICU admission and hence a HR could not be calculated, the association of pregabalin with ICU admission is left blank. Medications are displayed according to their recommended international non-proprietary names (riNN). ACEi = angiotensin converting enzyme inhibitors, ARBs = angiotensin receptor blockers, PPIs = proton pump inhibitors.